BCGM Wealth Management’s Gilead Sciences GILD Stock Holding History

BCGM Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Buy	14,503 +856	+6%	+$113K	0.39%	62
2026 Q1	$1.9M	Buy	13,647 +1,901	+16%	+$266K	0.48%	59
2025 Q4	$1.44M	Buy	+11,746	New	+$1.43M	0.37%	67
2022 Q2	–	Sell	-10,100	Closed	-$599K	–	106
2022 Q1	$599K	Buy	10,100 +412	+4%	+$26.3K	0.33%	59
2021 Q4	$703K	Buy	9,688 +372	+4%	+$25.6K	0.38%	57
2021 Q3	$604K	Buy	9,316 +770	+9%	+$54.1K	0.34%	60
2021 Q2	$584K	Buy	8,546 +881	+11%	+$58.8K	0.35%	59
2021 Q1	$509K	Buy	7,665 +1,530	+25%	+$98.7K	0.35%	58
2020 Q4	$410K	Buy	+6,135	New	+$370K	0.29%	60

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCGM Wealth Management's GILD Position: Q2 2026 in Review

BCGM Wealth Management increased its Gilead Sciences (GILD) stake by 6.3% in Q2 2026, buying an estimated $113K and bringing the position to 14,503 shares worth $1.83M. The position accounts for 0.39% of the portfolio, ranked #62.

BCGM Wealth Management first reported a position in GILD in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.9M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

BCGM Wealth Management held 14,503 shares of Gilead Sciences worth $1.83M as of Q2 2026.
BCGM Wealth Management bought 856 Gilead Sciences shares in Q2 2026, an estimated $113K.
Gilead Sciences made up 0.39% of BCGM Wealth Management's portfolio in Q2 2026, its #62 holding.
BCGM Wealth Management first reported a position in Gilead Sciences in Q4 2020 and has held it in 9 quarters since.
BCGM Wealth Management's Gilead Sciences position peaked at $1.9M in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on BCGM Wealth Management's 13F filing for Q2 2026, filed 4 Aug 2026.